Equity Overview
Price & Market Data
Price: $5.05
Daily Change: -$0.0405 / 0.80%
Daily Range: $4.91 - $5.73
Market Cap: $7,480,077
Daily Volume: 86,360
Performance Metrics
1 Week: -23.45%
1 Month: -48.32%
3 Months: -25.96%
6 Months: -67.63%
1 Year: -88.03%
YTD: -68.98%
Company Details
Employees: 4
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia; and CCP, multiple product candidates for gram-positive infections. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.